^
Association details:
| Biomarker: | HER-2 exon 20 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma
Published date:
06/03/2021
Excerpt:
Eighty-four organoids were established from patients with advanced lung adenocarcinoma….We demonstrated efficacy of poziotinib against ERBB2 exon 20 insertions and pralsetinib against RET-fusions...
DOI:
10.1158/1078-0432.CCR-20-5026
